The trial of "pharma bro" Martin Shkreli, accused of defrauding his hedge fund investors and misusing funds from a company he founded, Retrophin Pharmaceuticals, took a turn to a topic near and dear to a Forbes reporter’s heart: how the heck do you value a company that is not publicly traded?
from Forbes Real Time http://www.forbes.com/sites/matthewherper/2017/07/06/how-do-you-value-a-private-company-the-answer-could-affect-martin-shkrelis-fate/
via IFTTT
No comments:
Post a Comment